Recent progress in the management of pediatric chronic myeloid leukemia

Shima, Haruko; Shimada, Hideaki

doi:10.1007/s12185-022-03526-2

Cited by 2 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For children and adolescents with newly diagnosed chronic phase CML, only three TKIs have been approved by the Food and Drug Administration (FDA) (Imatinib since 2003, Dasatinib since 2017, Nilotinib since 2018). So far, some issues of TKI therapy remain unresolved, especially in pediatric cohort, such as hematological and non-hematological toxicity, long-term side effects, primary and secondary resistance [16][17][18][19][20][21][22]. The experience of CML therapy in children and adolescents is limited in Russian Federation.…”

Section: Chronic Phasementioning

confidence: 99%

Clinical course of chronic myeloid leukemia with T315I mutation of BCR-ABL gene in pediatric and adolescent patients

Sheveleva¹,

Morozova²,

Osipova³

et al. 2023

CTT

View full text Add to dashboard Cite

There is a limited number of publications on the incidence of different mutations in the BCR-ABL kinase domain, the efficacy and safety of therapy in children and adolescents with resistant forms of chronic myeloid leukemia (СML). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the only method able to cure the disease completely in pediatric and adolescent patients with CML, however, being associated with life-threatening complications. This article analyzes the course, treatment and outcomes of chronic myeloid leukemia in 3 pediatric patients pre-treated with tyrosine kinase inhibitors (TKI) who exhibited the T315I mutation in BCR-ABL kinase domain.

show abstract

Section: Chronic Phasementioning

confidence: 99%